The contract, which spreads over twelve months, involves supply of 1million units each month to AGN Tech.
Revolutions Medical CEO and chairman Ron Wheet said, "AGN Tech has done exceptional work introducing the RevVac safety syringes to the Brazilian marketplace."
AGN Tech president Carlos Carvalho said that the RevVac safety syringes provide quality and value to the expanding Brazilian marketplace.
"I feel we can continue to capture market share with all the positive benefits the RevVac product has to offer," Carvalho added.
